Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

Retrospective Assessment of Outcomes Following Superficial Vein Thrombosis in Cancer Patients

Mina Gendy, DO, Marie Anne Christine Buteau, MD, Marc Braunstein, MD PhD

Blood (2019) 134 (Supplement_1): 3655.

https://doi.org/10.1182/blood-2019-131978

Published: 2019

Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 690.

https://doi.org/10.1182/blood-2018-99-110388

Published: 2018

Journal Articles

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Vishal K Gupta, MD, Paul White, MD, Vaishali Sanchorawala, MD, Karen Quillen, MD MPH, Shayna Sarosiek, MD, Dina Brauneis, NP, John Mark Sloan, MD

Blood (2018) 132 (Supplement 1): 5738.

https://doi.org/10.1182/blood-2018-99-110230

Published: 2018

Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Blood (2017) 130 (Supplement 1): 188.

https://doi.org/10.1182/blood.V130.Suppl_1.188.188

Published: 2017

Journal Articles

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Gaelle Fossard, MD, Vincent Alcazer, MD, Marie Balsat, MD, Helene Labussiere-Wallet, MD, Stephane Morisset, Stat, Mohamad Sobh, Isabelle Tigaud, MD, Pierre Sujobert, MD PhD, Mauricette Michallet, MD PhD, Franck Emmanuel Nicolini, MD PhD

Blood (2017) 130 (Supplement 1): 2900.

https://doi.org/10.1182/blood.V130.Suppl_1.2900.2900

Published: 2017

Journal Articles

Portal Vein Thrombosis in Adult Omani Patients-a Retrospective Study

Khalid Al Hashmi, MD, Lamia Al Aamri, Anil Pathare, MD PhD FCPS, MBBS, Al Lamki Sulayma, Murtadha K. Al-Khabori, BSc,MDFRCPC,MSc

Blood (2017) 130 (Supplement 1): 4909.

https://doi.org/10.1182/blood.V130.Suppl_1.4909.4909

Published: 2017

Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

Andres Forero-Torres, MD, Seth Rosen, MD, David C. Smith, MD, Glenn Lesser, MD, Julio Peguero, MD, Shilpa Gupta, MD, Justin M. Watts, MD, Marcus Noel, MD, Razelle Kurzrock, MD, Haeseong Park, MD, Patricia LoRusso, DO, Catherine C. Coombs, MD, Fred Zheng, MD, Julie Switzky, RN, Swamy Yeleswaram, PhD, Gerald Falchook, MD

Blood (2017) 130 (Supplement 1): 4048.

https://doi.org/10.1182/blood.V130.Suppl_1.4048.4048

Published: 2017

Journal Articles

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1 R132 Mutations

Blood (2016) 128 (22): 1073.

https://doi.org/10.1182/blood.V128.22.1073.1073

Published: 2016

Journal Articles

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Timothy A. Yap, MD PhD, Jane N. Winter, MD, John P. Leonard, MD, Vincent Ribrag, MD, Anastasia Constantinidou, MD, Lisa Giulino-Roth, MD, Jean-Marie Michot, MD, Tariq A Khan, MD, Thierry Horner, PhD, Jennifer Carver, Teodora Pene Dumetrescu, PhD, Zangdong He, PhD, Michael T. McCabe, PhD, Caretha L. Creasy, PhD, Arindam Dhar, MBBS, MD PhD, Christopher Carpenter, MD PhD, Peter M Johnson, MA, MD

Blood (2016) 128 (22): 4203.

https://doi.org/10.1182/blood.V128.22.4203.4203

Published: 2016

Journal Articles

Prevalence and Risk Predictive Factors of Comorbid Malignancies in Patients with Chronic Myeloid Leukemia

Tong-Yoon Kim, MD, Sung-Eun Lee, Soo-Hyun Kim, Soo-Young Choi, Eun-Jung Jang, Dong-Wook Kim, MD PhD

Blood (2016) 128 (22): 1900.

https://doi.org/10.1182/blood.V128.22.1900.1900

Published: 2016

Journal Articles

Clinical Effects of IDH1/2-Mutant Inhibitors in IDH1/ 2-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Suggestions from Ex Vivo Experiments

Remco Molenaar, M.Sc., Tomas Radivoyevitch, PhD, Mohammed Khurshed, MD, Eiju Negoro, MD, PhD, Bartlomiej P Przychodzen, MSc, Hetty E. Carraway, MD MBA, Cornelis J van Noorden, PhD, Jaroslaw P. Maciejewski, MD, PhD, FACP

Blood (2016) 128 (22): 4308.

https://doi.org/10.1182/blood.V128.22.4308.4308

Published: 2016

Journal Articles

Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling

Maximilian Kordes, Michael Röring, Christoph Heining, Sandra Braun, Barbara Hutter, Daniela Richter, Christina Geörg, Claudia Scholl, Wilfried Roth, Andreas Rosenwald, MD, Eva Geissinger, Christof von Kalle, Dirk Jäger, Benedikt Brors, Wilko Weichert, Carsten Grüllich, Hanno Glimm, Tilman Brummer, PhD, Stefan Fröhling

Blood (2015) 126 (23): 1631.

https://doi.org/10.1182/blood.V126.23.1631.1631

Published: 2015

Journal Articles

Secondary Malignancies in Mantle Cell Lymphoma

Sandhya Talakokkla, MD, Renuka Mahatara, BS, Christine A Welch, MS, Arun Nagarajan, MD

Blood (2015) 126 (23): 5596.

https://doi.org/10.1182/blood.V126.23.5596.5596

Published: 2015

Journal Articles

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Frank Giles, MD MB, FRCPI, FRCPath, Sarina A. Piha-Paul, MD, Alexander I. Spira, PhD MD FACP, Fadi Braiteh, MD CPI, Julio Antonio Peguero, MD, Daniel L. Spitz, MD FACP, James A. Knost, MD, Lee Schwartzberg, MD FACP, Steven Stein, MD, August J. Salvado, MD, Claudia Lebedinsky, MD, Barinder Kang, PhD, Eric Slosberg, PhD

Blood (2014) 124 (21): 4818.

https://doi.org/10.1182/blood.V124.21.4818.4818

Published: 2014

Journal Articles

A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia

Anuhar Chaturvedi, PhD, Michelle Maria Araujo Cruz, Ramya Goparaju, Nidhi Jyotsana, Heike Baehre, PhD, Kerstin Goerlich, Renate Schottmann, Matthias Preller, PhD, Eduard A. Struys, PhD, Arnold Kloos, PhD, Volkhard Kaever, PhD, Arnold Ganser, Felicitas Thol, MD, Michael Heuser, MD

Blood (2014) 124 (21): 3598.

https://doi.org/10.1182/blood.V124.21.3598.3598

Published: 2014

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Fátima de la Cruz Vicente, Estrella Carrillo Cruz, María Solé Rodríguez, Ana Marín Niebla, Eduardo Ríos Herranz, María Luz Martino Galiana, Jose Falantes González, Isabel Montero Cuadrado, Jose González Campos, Ildefonso Espigado Tocino, Jose A Pérez-Simón

Blood (2013) 122 (21): 5087.

https://doi.org/10.1182/blood.V122.21.5087.5087

Published: 2013

Journal Articles

Updated Follow-Up In The CLL2007FMP Trial Supports The Non Superiority Of The Association Fludarabine-Cyclophosphamide (FC) Plus Campath Compared To FC Plus Rituximab and Points Out The Importance Of Minimal Residual Disease, By 6-Color Flow Cytometry Technique, On Progression Free Survival

Pierre Feugier, MD, PhD, Remi Letestu, MD, Sylvie Chevret, Thérèse Aurran, MD, Beatrice Mahe, Bruno Cazin, MD, Olivier Tournilhac, MD, PhD, Hervé Maisonneuve, Olivier Casasnovas, MD, Alain Delmer, MD, Véronique Leblond, MD, PhD, Bruno Royer, MD, Brigitte Corront, MD, Roselyne Delepine, Sandrine Vaudaux, Eric Van Den Neste, MD, PhD, Marie C Béné, PharmSciD, PhD, Florence Cymbalista, MD, PhD, Stéphane Leprêtre, MD

Blood (2013) 122 (21): 2870.

https://doi.org/10.1182/blood.V122.21.2870.2870

Published: 2013

Journal Articles

Occurrence of Neoplastic Diseases in a Large Cohort of Thalassemic Patients in Greece

Alexandra Kouraklis, MD, PhD, Antonia Chatziliami, MD, Antonis Kattamis, MD, PhD, Efthimia Vlachaki, MD, PhD, Evangelos Briasoulis, MD, PhD, Ioannis Lafiatis, MD, Polyxeni Lampropoulou, MD, Christina Fragodimitri, MD, Aggeliki Moira, MD, Argiris Symeonidis, MD, PhD

Blood (2012) 120 (21): 3264.

https://doi.org/10.1182/blood.V120.21.3264.3264

Published: 2012

NARROW

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Retrospective Assessment of Outcomes Following Superficial Vein Thrombosis in Cancer Patients

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Portal Vein Thrombosis in Adult Omani Patients-a Retrospective Study

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1 R132 Mutations

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Prevalence and Risk Predictive Factors of Comorbid Malignancies in Patients with Chronic Myeloid Leukemia

Clinical Effects of IDH1/2-Mutant Inhibitors in IDH1/ 2-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Suggestions from Ex Vivo Experiments

Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling

Secondary Malignancies in Mantle Cell Lymphoma

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Updated Follow-Up In The CLL2007FMP Trial Supports The Non Superiority Of The Association Fludarabine-Cyclophosphamide (FC) Plus Campath Compared To FC Plus Rituximab and Points Out The Importance Of Minimal Residual Disease, By 6-Color Flow Cytometry Technique, On Progression Free Survival

Occurrence of Neoplastic Diseases in a Large Cohort of Thalassemic Patients in Greece

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only